PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update

References

• ReussRRetzlaffKVogelSFrankeFEOschmannPAutoimmune hepatitis after high-dose intravenous methylprednisolone pulse in RR-MSCent Eur J Med200723356359
   Google Scholar
• PRISMS Study GroupRandomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAMultiple Sclerosis Collaborative Research GroupIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• ReussRPohleSRetzlaffKHembergerJOschmannPInterferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing–remitting multiple sclerosisNeuroimmunomodulation200916317117619246939
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
   PubMed Web of Science ®Google Scholar
• GalettaSLThe controlled high risk Avonex multiple sclerosis trial (CHAMPS study)J Neuroophthalmol200121429229511756862
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery-other-day interferon beta-1b versus once-weekly interferon beta-1b for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet200235993161453146011988242
   PubMed Web of Science ®Google Scholar
• BailonPBertholdWPolyethylene glycol-conjugated pharmaceutical proteinsPharm Sci Technolo Today199818352356
   Google Scholar
• PisalDSKosloskiMPBalu-IyerSVDelivery of therapeutic proteinsJ Pharm Sci20109962557257520049941
   PubMed Web of Science ®Google Scholar
• ChanYPMeyrueixRKravtzoffRNicolasFLundstromKReview on Medusa: a polymer-based sustained release technology for protein and peptide drugsExpert Opin Drug Deliv20074444145117683256
   PubMed Web of Science ®Google Scholar
• HarrisJMChessRBEffect of pegylation on pharmaceuticalsNat Rev Drug Discov20032321422112612647
   PubMed Web of Science ®Google Scholar
• DelgadoCFrancisGEFisherDThe uses and properties of PEG-linked proteinsCrit Rev Ther Drug Carrier Syst199293–42493041458545
   PubMed Web of Science ®Google Scholar
• CalicetiPVeroneseFMPharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugatesAdv Drug Deliv Rev200355101261127714499706
   PubMed Web of Science ®Google Scholar
• WangXIshidaTKiwadaHAnti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomesJ Control Release2007119223624417399838
   PubMed Web of Science ®Google Scholar
• RajanRSLiTArasMModulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case studyProtein Sci20061551063107516597829
   PubMed Web of Science ®Google Scholar
• YamamotoYTsutsumiYYoshiokaYSite-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivityNat Biotechnol200321554655212665803
   PubMed Web of Science ®Google Scholar
• ZhaiYZhaoYLeiJSuZMaGEnhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weightJ Biotechnol20091423–425926619497340
   PubMed Web of Science ®Google Scholar
• HershfieldMSPEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 yearsClin Immunol Immunopathol1995763 Pt 2S228S2327554473
   PubMedGoogle Scholar
• ReddyKRWrightTLPockrosPJEfficacy and safety of pegylated (40-kd) interferon alpha-2a in noncirrhotic patients with chronic hepatitis CHepatology200133243343811172346
   PubMed Web of Science ®Google Scholar
• GluePFangJWRouzier-PanisRHepatitis C Intervention Therapy GroupPegylated interferon alpha-2b: pharmacokinetics, safety, and preliminary efficacy dataClin Pharmacol Ther200068555656711103758
   PubMed Web of Science ®Google Scholar
• RaoHYLiJZhangLF[Effect of pegylated interferon beta-1-a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis.]Zhonghua Yi Xue Za Zhi200888296100 Chinese.18353212
   PubMedGoogle Scholar
• BasuAYangKWangMStructure-function engineering of interferon beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylationBioconjug Chem200617361863016704199
   PubMed Web of Science ®Google Scholar
• MagerDENeuteboomBJuskoWJPharmacokinetics and pharmacodynamics of pegylated IFN-beta 1a following subcutaneous administration in monkeysPharm Res2005221586115771230
   PubMed Web of Science ®Google Scholar
• HuXMillerLRichmanSA novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyJ Clin Pharmacol201252679880821680782
   PubMed Web of Science ®Google Scholar
• BakerDPLinEYLinKN-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis modelBioconjug Chem200617117918816417267
   PubMed Web of Science ®Google Scholar
• KieseierBCCalabresiPAPegylation of interferon-beta-1a: a promising strategy in multiple sclerosisCNS Drugs201226320521422201341
   PubMed Web of Science ®Google Scholar
• SjogrenMHSjogrenRJrLyonsMFAntiviral response of HCV genotype 1 to consenus interferon and ribavirin versus pegylated interferon and ribavirinDig Dis Sci20075261540154717406822
   PubMed Web of Science ®Google Scholar
• FonsecaMCBranco de AraujoGTAraujoDVCost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in BrazilBraz J Infect Dis200913319119920191195
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [homepage on the Internet]. Efficacy and Safety Study of BIIB017 (ADVANCE). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00906399?term=nct00906399&rank=1. Accessed May 13, 2013.
   Google Scholar
• BendeleASeelyJRicheyCSennelloGShoppGRenal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteinsToxicol Sci19984221521579579027
   PubMed Web of Science ®Google Scholar
• YoungMAMalavalliAWinslowNVandegriffKDWinslowRMToxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeysTransl Res2007149633334217543852
   PubMed Web of Science ®Google Scholar
• Final report on the safety assessment of triethylene glycol and PEG-4Int J Toxicol200625Suppl 212113817090481
   PubMed Web of Science ®Google Scholar
• SinakosEGigiELallaTHealth-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatmentHippokratia201014212212520596269
   PubMed Web of Science ®Google Scholar
• BonkovskyHLWoolleyJMConsensus Interferon Study GroupReduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapyHepatology19992912642709862876
   PubMed Web of Science ®Google Scholar
• BukowskiRTendlerCCutlerDRoseELaughlinMMStatkevichPTreating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulationCancer200295238939612124839
   PubMed Web of Science ®Google Scholar
• MaruDSBruceRDBasuSAlticeFLClinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsClin Infect Dis200847795296118715156
   PubMed Web of Science ®Google Scholar